Health ❯ Healthcare ❯ Medical Research ❯ Clinical Trials

Cancer Treatment

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

Approval by October 9, 2026 would establish the first immunotherapy-based adjuvant option for patients with dMMR/MSI-H stage III colon cancer.

Tango’s PRMT5 Inhibitor Plus Daraxonrasib Shows 92% Response in Biomarker‑Selected Pancreatic Cancer

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

Selpercatinib Dramatically Cuts Recurrence in Early-Stage RET-Positive Lung Cancer

Implanted Cesium-131 Tiles Cut Recurrences and Boost Survival in ROADS Phase III Trial

Imfinzi With Enfortumab Vedotin Improves Survival in Phase III Bladder Cancer Trial

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

Single CAR T Infusion Clears Residual Disease in High-Risk Smoldering Myeloma Trial

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Pooled Data Tie Early AE Management to Greater Zolbetuximab Benefit in Gastric/GEJ Cancer

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Pliant’s PLN-101095 With Keytruda Shows Early Responses in PD-1–Refractory Solid Tumors

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

OS Therapies Posts Significant 2-Year Survival Gain for OST-HER2 in Metastatic Osteosarcoma

Once-Monthly Subcutaneous Amivantamab Plus Lazertinib Shows High Response in Untreated EGFR‑Mutated NSCLC